Filtering bleb activation in the early post-operative period after fistulizing surgery

The article presents a case report of a patient with a cystic bleb in the early postoperative period after trabeculectomy. Patient complained of discomfort in a recently (4 weeks) operated eye. Medical regimen administered previously had been taken irregularly. Biomicroscopy revealed a high, encapsulated cystic bleb with thin walls and hyperemia. Intraocular pressure at the moment of examination was 27 mmHg. Local hypotensive therapy had been neglected by the patient. A local anti-inflammatory (tobramycin / dexamethasone fixed combination) and hypotensive (brimonidine / timolol fixed combination) therapy was administered. 24 hours later, when intraocular pressure decreased to 20 mmHg, a needle revision procedure was conducted for partial bleb wall destruction and subconjunctival injection of dexamethasone, fluorouracil and ranibizumab. During the next day examination the bleb was diffuse, with less hyperemia and an abundance of conjunctival microcysts in the central bleb’s zone. Intraocular pressure was 10.2 mmHg. No choroidal detachment was noted during ophthalmoscopy and OCT examination. The patient continued anti-inflammatory therapy. Another needling procedure with the same drug combination was repeated two weeks after due to an increased hyperemia. At the end of the four-week follow-up period the filtering bleb remained diffuse and the intraocular pressure was 13.2 mmHg. Dexamethasone drops were prescribed to be instilled 1‑2 times a day for a month. This case report demonstrates the method of restoring a functioning filtering bleb by the needle revision with antiinflammatory, cytostatic and anti-VEGF therapy for prolonging the hypotensive effect of a trabeculectomy in the presence of wound healing.

1. Bettin P., Khaw P. T. Postoperative management of penetrating and nonpenetrating external filtering procedures. Glaucoma Surgery. Dev. Ophthalmol. 2012; 50: 48‑63.

2. Shmyreva V. F., Petrov S. Yu., Antonov A. A., Pimenidi M. K. [Controlled cytostatic therapy in the early postoperative period after glaucoma surgery (preliminary report)]. Kontroliruemaya tsitostaticheskaya terapiya v rannie sroki posle antiglaukomatoznoi khirurgii (predvaritel’nye rezul’taty). [Annals of ophthalmology]. Vestnik oftal’mologii 2007; 1: 12‑14. (in Russ.).

3. Singh R. P., Goldberg I., Mohsin M. The efficacy and safety of itraoperative and / or postoperative 5‑fluorouracil in trabeculectomy and phacotrabeculectomy. Clin. Experiment. Ophtalmol. 2001; 29 (5): 296‑302.

4. Senger D. R., Galli S. J., Dvorak A. M., Perruzzi C. A., Harvey V. S., Dvorak H. F. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science. 1983; 219: 983‑985.

5. Berkovic A., Sirois M. G. Vascular permeability induced by VEGF family members in vivo: Role of endogenous PAF and NO synthesis. J Cell Biochem. 2007; 100 (3): 727‑737.

6. Ferrara N. Molecular and biological properties of vascular endothelial growth factor. J Mol Med. 1999; 77: 527‑543.

7. Gavard J., Gutkind J. S. VEGF controls endothelial-cell permeability by promoting the beta-arrestin-dependent endocytosis of VE-cadherin. Nat Cell Biol. 2006; 8:1223‑1234.

8. Budzinskaya M. V. [New approach to subretinal neovascular membrane diagnostics and treatment]. Sistema novykh podkhodov k diagnostike i lecheniyu subretinal’noi neovaskulyarnoi membrany. [Med. Sc. D. thesis]. Мoscow, 2011. Dissertatsiya na soiskanie uchenoi stepeni doktora meditsinskikh nauk. (in Russ.).

9. Budzinskaya M. V., Pogoda T. V., Strelkova I. D., Chikun E. A., Schegoleva I. V., Kazaryan E. E., Galoyan N. S. [The impact of genetic mutations on the subretinal neovascularization clinical picture. Report № 2. The role of HTRA и VEGF genetic polymorphism]. Vliyanie geneticheskikh mutatsii na klinicheskuyu kartinu subretinal’noi neovaskulyarizatsii. Soobshchenie 2. Rol’ polimorfizmov genov HTRA i VEGF. [Annals of ophthalmology]. Vestnik oftal’mologii 2011; 4: 9‑16. (in Russ.).

10. Karp J. E., Broder S. Molecular foundations of cancer: new targets for intervention. Nat. Med. 1995; 4 (1): 309‑320.

11. Bochmann F., Kaufmann C., Becht C. N., Guber I., Kaiser M., Bachmann L. M., Thiel M. A. ISRCTN12125882 — Influence of topical anti-VEGF (Ranibizumab) on the outcome of filtration surgery for glaucoma — Study Protocol. BMC Ophthalmol. 2011; 11: 1.

12. Kahook M. Y. Bleb morphology and vascularity after trabeculectomy with intravitreal ranibizumab: a pilot study. Am J Ophthalmol. 2010; 150 (3): 399‑403.

13. Horsley M. B., Kahook M. Y. Anti-VEGF therapy for glaucoma. Curr Opin Ophthalmol. 2010; 21 (2): 112‑117.

14. How A., Chua J. L., Charlton A., Su R., Lim M., Kumar R. S., Crowston J. G., Wong T. T. Combined treatment with bevacizumab and 5‑fluorouracil attenuates the postoperative scarring response after experimental glaucoma filtration surgery. Invest. Ophthalmol. Vis. Sci. 2010; 51 (2): 928‑932.

15. Sengupta S., Venkatesh R., Ravindran R. D. Safety and Efficacy of Using Off-label Bevacizumab Versus Mitomycin C to Prevent Bleb Failure in a Single-site Phacotrabeculectomy by a Randomized Controlled Clinical Trial. J. Glaucoma. 2012; 21 (7): 450‑459.

16. Klettner A., Roider J. Comparison of bevacizumab, ranibizumab, and pegaptanib in vitro: efficiency and possible additional pathways. Invest Ophthalmol Vis Sci. 2008; 49 (10): 4523‑4527.

17. Camejo L., Noecker R. J. Bleb Needling. Glaucoma Today. 2007.

18. Petrov S. Yu. [Bleb classification]. Klassifikatsii fil’tratsionnykh podushek. [National Journal glaucoma]. Natsional’nyi zhurnal glaukoma 2014; 13 (3): 85‑98. (in Russ.).

19. Petrov S. Yu., Novikov I. A., Dugina A. E. [Methods for assessing the functional state of the filtering bleb after glaucoma surgery]. Sposob otsenki funktsional’nogo sostoyaniya fil’tratsionnoi podushki posle antiglaukomatoznoi operatsii. [RU patent]. Patent na izobretenie 2423069. 19.11.2009. (in Russ.).

20. Addicks E. M., Quigley H. A., Green W. R., Robin A. L: Histologic characteristics of filtering blebs in glaucomatous eyes. Arch Ophthalmol. 1983; 101: 795.

21. Lebedev O. I. [The concept of excessive scarring after glaucoma surgery]. Kontseptsiya izbytochnogo rubtsevaniya tkanei glaza posle antiglaukomatoznykh operatsii. [Annals of ophthalmology]. Vestnik oftal’mologii 1993; 1: 36‑39. (in Russ.).

22. Shmyreva V. F., Petrov S. Yu., Makarova A. S. [Causes of long-term decrease of glaucoma surgery hypotensive effect and possibilities of its enhancement]. Prichiny snizheniya otdalennoi gipotenzivnoi effektivnosti antiglaukomatoznykh operatsii i vozmozhnosti ee povysheniya. [Glaucoma]. Glaukoma 2010. 2: 43‑49. (in Russ.).

23. Wong J., Wang N., Miller J. W., Schuman J. S. Modulation of human fibroblast activity by selected angiogenesis inhibitors. Exp. Eye. Res. 1994; 58: 439‑451.

24. Budzinskaya M. V., Gurova I. V. [Subretinal neovascular membrane in patients with age-related macular degeneration]. Subretinal’naya neovaskulyarnaya membrana pri vozrastnoi makulyarnoi degeneratsii. [Annals of ophthalmology]. Vestnik oftal’mologii 2006; 122 (4): 49‑54. (in Russ.).

25. Budzinskaya M. V., Pogoda T. V., Generosov E. V., Chikun E. A., Gurova I. V., Schegoleva I. V., Sizova M. V. [Modern farmacogenetical approach to treating age-related macular degeneration]. Sovremennye farmakogeneticheskie podkhody k lecheniyu vozrastnoi makulyarnoi degeneratsii. [Annals of ophthalmology]. Vestnik oftal’mologii.2013; 129 (5): 127‑135. (in Russ.).

26. Budzinskaya M. V., Gurova I. V., Schegoleva I. V., Loshenov V. B., Shevchik S. A., Kuzmin S. G., Vorozhtsov G. N. [Combined therapy of exudative age-related macular degeneration]. Kombinirovannaya terapiya ekssudativnoi formy vozrastnoi makulyarnoi degeneratsii setchatki. [Photodynamic therapy and photodiagnostics]. Fotodinamicheskaya terapiya i fotodiagnostika. 2013; 1: 20‑24. (in Russ.).